Phase III Endpoint Hit For Novartis's Gilenya Follow-On In Progressive MS
Executive Summary
Novartis AG's Gilenya follow-on drug, BAF312 (siponimod), has met its primary endpoint in the Phase III EXPAND trial, giving the drug a positive outlook for approval as a treatment for underserved secondary progressive multiple sclerosis (SPMS) patients.
You may also be interested in...
Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy
Roche is taking no chances with its newly approved multiple sclerosis drug Ocrevus and has set a cost that ensures price is no barrier to treatment.
Novartis' Siponimod Emerges With Solid Safety, Skirts Gilenya's Heart Effects
Positive results from the Phase III EXPAND study of oral siponimod in secondary progressive multiple sclerosis, presented at ECTRIMS, lift Novartis ahead of Gilenya patent expiry and may be enough to support early approval.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.